Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells

Ríos-Huerta, Regina; Monreal‐Escalante, Elizabeth; Govea‐Alonso, Dania O.; Angulo, Carlos; Rosales‐Mendoza, Sergio

doi:10.1007/s00299-016-2088-6

Cited by 27 publications

(14 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For quantitative ELISA, a protocol described elsewhere was applied (Ríos-Huerta et al, 2017). Briefly, protein extracts were obtained as described above and diluted with 0.2 M carbonate buffer (pH = 9.6).…”

Section: Methodsmentioning

confidence: 99%

Algevir: An Expression System for Microalgae Based on Viral Vectors

et al. 2017

View full text Add to dashboard Cite

The use of recombinant algae for the production of valuable compounds is opening promising biotechnological applications. However, the development of efficient expression approaches is still needed to expand the exploitation of microalgae in biotechnology. Herein, the concept of using viral expression vectors in microalgae was explored for the first time. An inducible geminiviral vector leading to Rep-mediated replication of the expression cassette allowed the production of antigenic proteins at high levels. This system, called Algevir, allows the production of complex viral proteins (GP1 from Zaire ebolavirus) and bacterial toxin subunits (B subunit of the heat-labile Escherichia coli enterotoxin), which retained their antigenic activity. The highest achieved yield was 1.25 mg/g fresh biomass (6 mg/L of culture), which was attained 3 days after transformation. The Algevir system allows for a fast and efficient production of recombinant proteins, overcoming the difficulties imposed by the low yields and unstable expression patterns frequently observed in stably transformed microalgae at the nuclear level; as well as the toxicity of some target proteins.

show abstract

Section: Methodsmentioning

confidence: 99%

Algevir: An Expression System for Microalgae Based on Viral Vectors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The fusion of the HLT B subunit (HLTB) with the linear B cell epitope of the outer membrane protein (OmpC) of Aeromonas hydrophila can stimulate the production of neutralizing antibodies against this linear epitope and generate a Th2 type mixed auxiliary T cell immune response (Sharma et al, 2017). The two epitopes of the Zairian Ebola virus GP1 protein, which can be recognized by neutralizing antibodies, were coupled with HLTB protein to form recombinant antigen HLTB-EBOV expressed in plant tissues, and immunizing mice with the recombinant antigen presented by the plant induced a higher level of IgA and IgG responses (Rios-Huerta et al, 2017). The CT subunit-B (CTB) can be used as a powerful adjuvant to generate mucosal immunity due to its strong affinity to the GM1 ganglioside receptor which is primarily located on mucosal epithelial cells (i.e., M cells) (Pinkhasov et al, 2010).…”

Section: Bacterial Toxin Proteinsmentioning

confidence: 99%

Application of built-in adjuvants for epitope-based vaccines

Yao

Zhao

Shao

et al. 2019

PeerJ

View full text Add to dashboard Cite

Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: (1) pattern recognition receptor ligands (i.e., toll-like receptors); (2) virus-like particle carrier platforms; (3) bacterial toxin proteins; and (4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles, lipid core peptides, and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

show abstract

“…Recent efforts by several organizations have focused on identifying effective therapies and developing appropriate vaccination strategies ( 33 ). Several drugs and vaccines have been developed against EBOV, and the production of low-cost drugs and vaccines against EBOV is essential for everyone, including those in the high-risk areas of the world, to be protected ( 26 , 34 ). As of the acquisition of better knowledge against the pathogen due to improvement in the field of genomics and proteomics, there has been expansion in the field of vaccine synthesis where epitope-based vaccines are gaining top priority ( 35 – 37 ).…”

Section: Introductionmentioning

confidence: 99%

Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus

et al. 2018

View full text Add to dashboard Cite

Ebola virus (EBOV), a member of the family Filoviridae, is responsible for causing Ebola virus disease (EVD) (formerly named Ebola hemorrhagic fever). This is a severe, often fatal illness with mortality rates varying from 50 to 90% in humans. Although the virus and associated disease has been recognized since 1976, it was only when the recent outbreak of EBOV in 2014–2016 highlighted the danger and global impact of this virus, necessitating the need for coming up with the effective vaccines and drugs to counter its pandemic threat. Albeit no commercial vaccine is available so far against EBOV, a few vaccine candidates are under evaluation and clinical trials to assess their prophylactic efficacy. These include recombinant viral vector (recombinant vesicular stomatitis virus vector, chimpanzee adenovirus type 3-vector, and modified vaccinia Ankara virus), Ebola virus-like particles, virus-like replicon particles, DNA, and plant-based vaccines. Due to improvement in the field of genomics and proteomics, epitope-targeted vaccines have gained top priority. Correspondingly, several therapies have also been developed, including immunoglobulins against specific viral structures small cell-penetrating antibody fragments that target intracellular EBOV proteins. Small interfering RNAs and oligomer-mediated inhibition have also been verified for EVD treatment. Other treatment options include viral entry inhibitors, transfusion of convalescent blood/serum, neutralizing antibodies, and gene expression inhibitors. Repurposed drugs, which have proven safety profiles, can be adapted after high-throughput screening for efficacy and potency for EVD treatment. Herbal and other natural products are also being explored for EVD treatment. Further studies to better understand the pathogenesis and antigenic structures of the virus can help in developing an effective vaccine and identifying appropriate antiviral targets. This review presents the recent advances in designing and developing vaccines, drugs, and therapies to counter the EBOV threat.

show abstract

Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells

Cited by 27 publications

References 39 publications

Algevir: An Expression System for Microalgae Based on Viral Vectors

Algevir: An Expression System for Microalgae Based on Viral Vectors

Application of built-in adjuvants for epitope-based vaccines

Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus

Contact Info

Product

Resources

About